Share

FDA Grants Orphan Drug Designation for Potential Treatment of Hypoparathyroidism

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AZP-3601, Amolyt Pharma’s clinical candidate for the treatment of hypoparathyroidism. “We believe the FDA’s granting of Orphan Drug Designation to AZP-3601 reflects the agency’s recognition that new and more effective treatment options are needed for this serious endocrine disorder,” says Endocrine...
Share

Phase III Trials Set After Potential Type 1 Diabetes Vaccine Shows Promise

[Editor’s note: This post has been updated to clarify that the meta-analysis published in Diabetologia and the Phase IIb trial were separate studies.] Earlier this fall, Phase IIb topline results of the DIAGNODE-2 trial demonstrated a potential type 1 diabetes vaccine GAD-alum —  an immunomodulating antigen-specific therapy – had a highly significant and clinically relevant...
Share

Pharmaceutical Companies Team Up to Develop Acromegaly Treatment

Two pharmaceutical companies will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration...
Share

Unprecedented: How COVID-19 Jump-Started Diabetes Care Innovations

EN1120_cover-small The Endocrine Society has been leading the charge for adopting innovative diabetes care models since 2018. However, the specter of the COVID-19 pandemic has forced the entire healthcare industry to rethink how patients are treated, resulting in an unprecedented wave of innovation that could revolutionize how care is delivered. In early March, Robert A. Gabbay,...
Share

Insulin Titration Software Combined with CGM Enables Patients with Diabetes to Improve Time in Range

First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources This past summer, Glytec published the first proof-of-concept study that combines FDA-cleared remote insulin titration software and data from continuous glucose monitoring (CGM) systems. Results of the study, presented at the American Diabetes Association’s...
Share

Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research

Dexcom last month announced it has signed a five-year collaboration agreement with the University of Virginia to advance its research and development efforts on continuous glucose monitoring-based solutions. The research partnership will center on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous glucose monitoring tools outside the type 1 diabetes market,...
Share

Endocrine Society Partners with Beyond Type 1 to Address Immediate Needs of People Struggling to Access Insulin

A new tool for anyone in the United States struggling to access life-sustaining insulin launched today at GetInsulin.org. Created by global diabetes nonprofit organization Beyond Type 1, GetInsulin.org connects people with diabetes who take insulin to assistance programs and low-cost solutions that match their unique situation. Insulin is a life-essential medicine for over seven million people with...
Show More

The endocrine system is a miracle of evolution — a highly complex machine that carries out multiple functions within the body with precision and efficiency. It’s no wonder that as our understanding of the endocrine system advances, the technology we use to study and care for it also becomes more advanced as it approaches the endocrine system in terms of sophistication. Whether that endocrinology technology takes the form of new, advanced medicines, sophisticated imaging and diagnostic technology, or innovative therapies that make life easier for patients, endocrine science continues to push the boundaries and enter new territory. For endocrinologists, staying informed about all of the latest advances in technology and effective treatment options mean better overall care for their patients.

This section compiles the latest news regarding technological advances in endocrinology, featuring articles written for and by the leading voices in endocrine science today. Here, you’ll find articles relating to all the most recent happenings in technology, techniques and general information of interest to endocrinologists. Keeping up with the latest advancements in the field will help you know where medicine has been, where it will advance next, and how it will look in the future. Endocrine News brings you everything you need to know about the future of endocrinology so you’ll know exactly when science catches up to your patients’ needs. The field of endocrinology continues to advance, and Endocrine News is your source for advancing your own knowledge of everything that’s going on for today and tomorrow.